Big Data Research Platform Aggregates, Interprets Molecular, Life Sciences Data

The new agreement also extends the user base for NextBio across Boehringer Ingelheim’s global research organization.

“Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies and has been a user of NextBio Research for the past year,” said Saeid Akhtari, NextBio president and chief executive officer. “This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology’s value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide.

“NextBio Research provides a comprehensive platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research,” Mr. Akhtari added. “Integrating proprietary analysis results with extensive curated content, NextBio enhances researchers’ ability to design experiments, test hypotheses, and validate results, leading to better target analysis, understanding of disease mechanisms, and analysis of results across species.”

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. It operates globally with 140 affiliates and more than 46,000 employees. The company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about EUR 14.7 billion. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

NextBio provides a cutting-edge scientific platform to aggregate and interpret large quantities of molecular and other life sciences data for research and clinical applications. NextBio’s platform integrates data from multiple repositories and diverse technologies by way of a unique correlation engine, which precomputes billions of significant connections between disparate public and proprietary clinical and research data. This feature enables interpretation of an individual’s molecular data.

Furthermore, the platform provides translational researchers with the capability to gaze across the clinical and molecular data of entire populations for clinical trial stratification and selection, hypotheses generation, and biomarker discovery. NextBio Clinical, which recently passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems. Backed by highly scalable, Big Data technology, it is capable of analyzing petabytes of data. NextBio’s platform is delivered as a software as a service (SaaS) system, resulting in fast deployment and rapid return on investment.

NextBio is currently used by researchers and clinicians in over 50 top commercial and academic institutions.

Related Links:
Boehringer Ingelheim
NextBio